In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone.

Objectives To evaluate the in vivo antibacterial efficacy of nemonoxacin, a novel C8-methoxy non-fluorinated quinolone in murine systemic and local infection models. Methods The efficacy of nemonoxacin in systemic infections was evaluated in mouse peritonitis models using isolates of methicillin-susceptible Staphylococcus aureus (MSSA, n = 1), methicillin-resistant S. aureus (MRSA, n = 1), methicillin- and levofloxacin-resistant Staphylococcus capitis (levofloxacin-resistant MRSC, n = 1), penicillin-intermediate Streptococcus pneumoniae (PISP, n = 1), penicillin-resistant S. pneumoniae (PRSP, n = 2), Enterococcus faecalis (n = 2, including 1 vancomycin-resistant Enterococcus, VRE) and Escherichia coli (n = 3). The local infections included mouse pulmonary infections caused by PRSP (n = 1), Klebsiella pneumoniae (n = 1) and mouse ascending urinary tract infection caused by E. coli (n = 1). Results In the mouse systemic infection model, nemonoxacin demonstrated potent activity against MSSA (ED50 = 2.08 mg/kg), MRSA (ED50 = 2.59 mg/kg), levofloxacin-resistant MRSC (ED50 = 2.52 mg/kg), PISP (ED50 = 5.47 mg/kg), PRSP (ED50 = 3.68–5.28 mg/kg) and E. coli (ED50 = 3.13–5.28 mg/kg), and moderate activity towards E. faecalis infection (ED50 = 8.48–15.16 mg/kg). The therapeutic efficacy of nemonoxacin was significantly higher (P < 0.01) than that of levofloxacin in infections caused by Gram-positive isolates (MSSA, MRSA, levofloxacin-resistant MRSC, PISP, PRSP and E. faecalis), but less potent than that of levofloxacin against E. coli infection (P < 0.01). Nemonoxacin in vivo efficacy results with Gram-positive isolates (2- to 5-fold ED50 advantage over levofloxacin) are consistent with the MIC data (4- to 16-fold MIC advantage of nemonoxacin over levofloxacin). In the mouse pulmonary infection model, nemonoxacin showed potent activity towards PRSP (higher than levofloxacin) and K. pneumoniae (lower than levofloxacin) infections. In the mouse ascending urinary tract infection model, nemonoxacin exhibited potent activity against E. coli infection (lower than levofloxacin). Conclusions The results validated the potent efficacy of nemonoxacin in vivo. The higher efficacy of nemonoxacin than of levofloxacin towards infections caused by Gram-positive cocci (especially MRSA, levofloxacin-resistant MRSC, PRSP and VRE) warrants investigation of its clinical use. [ABSTRACT FROM PUBLISHER]